A Study of CBP-1008 in Patients With Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this phase I study is to evaluate the safety and potential efficacy
and to determine the recommended phase 2 dose (RP2D) of CBP-1008, a bi-specific ligand
conjugated drugs in patients with advanced solid tumors.